<DOC>
	<DOCNO>NCT01841775</DOCNO>
	<brief_summary>Multicenter prospective follow-up control chronic hepatitis C genotypes 2/3 patient cohort treatment indication interferon α 2b ribavirin 24 week , verification sustain virological response week 48 . The eligibility criteria outcome measure follow Clinical Protocol Therapeutic Guidelines Chronic Viral Hepatitis C , publish Ministry Health : http : //portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf</brief_summary>
	<brief_title>Interferon α 2b Pharmacovigilance Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Genotype 2/3 Chronic Hepatitis C confirm biomolecular technology ( RNAVHC ) ; Treatment naive ; Signing Informed Consent Form ; Eligibility criteria outcome measure follow Clinical Protocol Therapeutic Guidelines Chronic Viral Hepatitis C , publish Ministry Health : http : //portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf Serious adverse event ; Intolerance treatment ; Lost follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Genotype 2/3</keyword>
	<keyword>Interferon α 2b</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Pharmacovigilance</keyword>
</DOC>